Medifast (NYSE:MED – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of -0.700–0.050 for the period, compared to the consensus estimate of -0.520. The company issued revenue guidance of $125.0 million-$145.0 million, compared to the consensus revenue estimate of $161.8 million.
Wall Street Analysts Forecast Growth
Separately, DA Davidson reaffirmed an underperform rating and issued a $17.50 price target on shares of Medifast in a research report on Monday, July 22nd.
Medifast Stock Performance
Medifast Company Profile
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Featured Articles
- Five stocks we like better than Medifast
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- From Tokyo to Wall Street: Japan’s Market Impact on U.S. Stocks
- Investing in Commodities: What Are They? How to Invest in Them
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- The 3 Best Retail Stocks to Shop for in August
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.